Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
Status:
Unknown status
Trial end date:
2019-10-30
Target enrollment:
Participant gender:
Summary
Undifferentiated thyroid cancer is the most malignant tumor of the thyroid gland, with a
median survival of only 3 months. Most undifferentiated cancers lose the chance of surgery
when they are first diagnosed. The current study, Nexavar, is used only for dedifferentiated
thyroid cancer and has not been applied to undifferentiated cancer. This study attempted to
apply it to preoperative treatment of undifferentiated cancer to see if it would shrink the
tumor and give the patient an opportunity for surgery.